Formulation and Evaluation of Mucoadhesive Based Buccal Tablet for Improved Bioavailability
Keywords:
Mucoadhesive Buccal Tablet, Buccal Drug Delivery, Bioavailability, Mucoadhesive PolymerAbstract
Mucoadhesive buccal drug delivery systems have gained considerable attention as an effective alternative to conventional oral dosage forms due to their ability to improve drug bioavailability, prolong drug release, and bypass first-pass hepatic metabolism. Buccal tablets are designed to adhere to the mucosal surface of the oral cavity, allowing controlled and sustained release of therapeutic agents directly into systemic circulation. The present study focuses on the formulation and evaluation of mucoadhesive based buccal tablets for enhanced drug delivery and improved bioavailability. Various mucoadhesive polymers such as hydroxypropyl methylcellulose (HPMC), carbopol, sodium alginate, and chitosan were utilized to prepare buccal tablets using the direct compression method. The formulated tablets were evaluated for physicochemical parameters including hardness, thickness, friability, weight variation, surface pH, swelling index, drug content uniformity, mucoadhesive strength, and in vitro drug release behavior. The results demonstrated that the optimized formulation exhibited satisfactory mucoadhesive properties, prolonged residence time, controlled drug release, and improved drug permeation through the buccal mucosa. The study concluded that mucoadhesive buccal tablets are a promising drug delivery system for enhancing therapeutic efficacy, patient compliance, and bioavailability of drugs with poor oral absorption and extensive first-pass metabolism.
References
World Health Organization. Ethics and governance of artificial intelligence for health. Geneva: World Health Organization; 2021.
U.S. Food and Drug Administration. Artificial Intelligence for Drug Development [Internet]. Silver Spring: FDA; content current 2026 May 1 [cited 2026 May 8]. Available from:https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development
U.S. Food and Drug Administration. Using artificial intelligence and machine learning in the development of drug and biological products: discussion paper. Silver Spring: FDA; 2023, revised 2025.
Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80-93.
Serrano DR, Luciano FC, Anaya BJ, et al. Artificial intelligence applications in drug discovery and the pharmaceutical industry. Pharmaceutics. 2024;16:1-28.
Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589.
Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493-500.
Graafsma J, Heringa M, Gebuis E, et al. The use of artificial intelligence to optimize medication alerts in clinical decision support systems: a systematic review. Int J Med Inform. 2024;185:105387.
Armando LG, et al. Clinical decision support systems to improve drug prescription and to reduce medication errors: a systematic review. BMC Med Inform Decis Mak. 2023;23:1-15.
Shahmoradi L, Safdari R, Ahmadi H, Zahmatkeshan M. Clinical decision support systems-based interventions to improve medication safety: a systematic review on features and effects. J Biomed Inform. 2021;117:103759.
Syrowatka A, Song W, Amato MG, et al. Computerized clinical decision support to prevent medication errors and adverse drug events. In: Making Healthcare Safer IV. Rockville: Agency for Healthcare Research and Quality; 2024.
Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347-1358.
Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24-29.
Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-477.
Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17(2):97-113.
Zhavoronkov A, Vanhaelen Q, Oprea TI. Will artificial intelligence for drug discovery impact clinical pharmacology? Clin Pharmacol Ther. 2020;107(4):780-785.
Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773-780.
Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. Future Healthc J. 2019;6(2):94-98.
Chen JH, Asch SM. Machine learning and prediction in medicine: beyond the peak of inflated expectations. N Engl J Med. 2017;376(26):2507-2509.
Downloads
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
